[China BD 2023] Zion Pharma and Roche enters a 680 million USD acquisition on HER2 TKI ZN-A-1041 (RG6596)

Announced Date: 2023-05-09 (May 9, 2023)

Asset Name: ZN-A-1041 (RG6596, perzebertinib)

Licensor (Seller): Zion Pharma (China)

Licensee (Buyer): Roche

.

Asset Modality: Small Molecule

Asset Target: tyrosine kinase inhibitor (TKI) that targets the human epidermal growth factor receptor 2 (HER2).

Potential Indication: HER2-positive breast cancer (HER-2+ BC)

Current Stage: Phase I

.

Scope of Authority:

Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.

.

Payment Detail:

Zion will receive

Upfront payment and near-term milestone payments up to $70 million,

Development, regulatory, and sales-based milestone payments of up to $610 million.

Tiered royalties on sales. 

.

Link:

Zion Pharma Announces Global Agreement with Roche to develop and commercialize a blood brain barrier penetrant oral HER2 tyrosine kinase inhibitor-苏州赞荣医药科技有限公司

.

Note:

Chinese Name of Zion Pharma, 赞荣医药